1801544-27-3

1801544-27-3 structure

Name: Losatuxizumab
Chemical Name: Losatuxizumab
CAS Number: 1801544-27-3
Molecular Formula:
Molecular Weight:
Catalog: Signaling Pathways JAK/STAT Signaling EGFR
Create Date: 2023-02-28 07:32:56
Modify Date: 2024-04-05 20:13:10
Losatuxizumab (ABT-806) is an anti-EGFR monoclonal antibody. Losatuxizumab binds to EGFR with EC50s of 0.96 nM for EGFR wild-type, 0.09 nM for EGFRC271A,C283A, 0.12 nM for EGFRvIII, 0.66 nM for EGFR1-501. Losatuxizumab can be used for research of EGFR-expressing cancers[1][2].

Name	Losatuxizumab

Description	Losatuxizumab (ABT-806) is an anti-EGFR monoclonal antibody. Losatuxizumab binds to EGFR with EC50s of 0.96 nM for EGFR wild-type, 0.09 nM for EGFRC271A,C283A, 0.12 nM for EGFRvIII, 0.66 nM for EGFR1-501. Losatuxizumab can be used for research of EGFR-expressing cancers[1][2].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> JAK/STAT Signaling >> EGFR Signaling Pathways >> Protein Tyrosine Kinase/RTK >> EGFR
In Vitro	Losatuxizumab (0.001 nM-100 nM) 可与表达 EGFRvIII 的细胞系 U87MGde2-7 结合[1]。 Losatuxizumab 抑制 NR6 huEGFRC271A,C283A 细胞系中 EGF 介导的 EGFR 磷酸化，IC50 为 1.2 nM[2]。
In Vivo	Lorigerlimab 在多种表达野生型 EGFR 的鳞状细胞癌异种移植模型中均具有抗肿瘤活性[1]。 Lorigerlimab (40 mg/kg, 腹腔注射) 显着抑制小鼠 U87MGde2-7 肿瘤的生长[1]。 Lorigerlimab (10 和 40 mg/kg，腹腔注射) 在 PDX GBM 模型 (SN0207 肿瘤) 中延长生存期并降低肿瘤中 pEGFR 水平[1]。 Animal Model: PDX GBM model (SN0207 tumor)[1] Dosage: 40 mg/kg Administration: i.p. Result: Prolonged survival rate, and reduced levels of pEGFR in tumor.
References	[1]. Reilly EB, et al. Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody. Mol Cancer Ther. 2015 May;14(5):1141-51. [2]. Phillips AC, et al. ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope. Mol Cancer Ther. 2016 Apr;15(4):661-9.

No Any Chemical & Physical Properties